摘要
背景:近年来,许多研究都致力于生物标志物在心力衰竭领域的应用。 目的:研究microRNAs转录后在心力衰竭诊断和治疗中的调控作用。 方法:文献检索集中在microRNAs在心力衰竭中的作用。 结果:microRNAs在心衰病理表现过程中表达和调控。这一广泛而未知的遗传印记领域由小的非编码RNA分子组成,在特定条件或压力下,这些基因印记会被上调,并从器官释放到血液中。使用基于基因的策略治疗心衰在生物医学领域引起了极大的兴趣,因为它们可以作为生物标志物,提供有关心脏状态和功能的信息。由于它们能够在不改变基因序列的情况下诱导细胞水平的变化,因此它们似乎也是具有治疗潜力的有前途的工具。此外,随着microRNAs鉴定技术的基因组测序、量化和合成技术的进步,以及对microRNAs生物学及其在HF中的作用的研究进展,microRNAs有望用于HF患者并对其预后产生良好的影响。 结论:MicroRNAs参与了心力衰竭进展的多生物学过程的调控。需要更多的研究来实现microRNAs在心衰治疗中的临床应用价值。
关键词: 心脏纤维化,心肌细胞,心脏重塑,炎症,细胞治疗,再生。
Current Medicinal Chemistry
Title:MicroRNAs in the Management of Heart Failure
Volume: 28 Issue: 24
关键词: 心脏纤维化,心肌细胞,心脏重塑,炎症,细胞治疗,再生。
摘要:
Background: In recent years much research has been devoted to the deployment of biomarkers in the field of heart failure.
Objectives: To study the potential of post-transcriptional regulation by microRNAs on the diagnosis, management and therapy of heart failure.
Methods: Literature search focuses on the role of microRNAs in heart failure.
Results: MicroRNAs are expressed and regulated in the course of the pathological manifestations of heart failure (HF). This wide and uncharted area of genetic imprints consisting of small non-coding RNA molecule is upregulated and released into the bloodstream from organs under certain conditions and or stress. The use of genetically based strategies for the management of HF has gained great interest in the field of biomedical science because they can be used as biomarkers providing information regarding cardiac status and function. They also appear as promising tools with therapeutic potential because of their ability to induce changes at the cellular level without creating alterations in the gene sequence. In addition, with the advances in genomic sequencing, quantification and synthesis in technologies of microRNAs identification as well as the growing knowledge of the biology of miRNAs and their involvement in HF, it is expected to favorably affect the prognosis of HF patients.
Conclusion: MicroRNAs are involved in the regulation of multibiological processes involved in the progress of heart failure. More studies are needed to achieve a clinical valuable implementation of microRNAs in the management of HF.
Export Options
About this article
Cite this article as:
MicroRNAs in the Management of Heart Failure, Current Medicinal Chemistry 2021; 28 (24) . https://dx.doi.org/10.2174/0929867328666210218181441
DOI https://dx.doi.org/10.2174/0929867328666210218181441 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial (No-reflow After Primary Coronary Interventions: How to Prevent and How to Treat it?)
Current Vascular Pharmacology Potential Cardio-Protective Agents: A Resveratrol Review (2000-2019)
Current Pharmaceutical Design Role of the Renin-Angiotensin-Aldosterone System in the Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Mean Platelet Volume: A Link Between Thrombosis and Inflammation?
Current Pharmaceutical Design Endogenous and Exogenous CNS Derived Stem / Progenitor Cell Approaches for Neurotrauma
Current Drug Targets The Renin-Angiotensin Systems: Evolving Pharmacological Perspectives for Cerebroprotection
Current Pharmaceutical Design Prevention of Left Ventricular Remodelling after Acute Myocardial Infarction: An Update
Recent Patents on Cardiovascular Drug Discovery Cardiovascular Side Effects of New Antidepressants and Antipsychotics: New Drugs, old Concerns?
Current Pharmaceutical Design Aortic Arch Calcification and Mortality in Chronic Hemodialysis Patients
Reviews on Recent Clinical Trials Biochemical Markers of Cardiovascular Damage from Tobacco Smoke
Current Pharmaceutical Design Losing Control: Positive and Negative Feedback in the Renin Angiotensin System
Current Hypertension Reviews How to Measure Exercise Performance
Current Respiratory Medicine Reviews mTOR in Growth and Protection of Hypertrophying Myocardium
Cardiovascular & Hematological Agents in Medicinal Chemistry Aldosterone, From (Patho)Physiology to Treatment in Cardiovascular and Renal Damage
Current Vascular Pharmacology Editorial from Editor-in-Chief (Thrombolytic and Catheter-Directed Therapy for Pulmonary Embolism: The Paradox of Clinical Outcomes and Theory)
Current Respiratory Medicine Reviews Cellular Cardiomyoplasty and Cardiac Regeneration
Current Cardiology Reviews New Strategies for Managing Anemia of Chronic Kidney Disease
Cardiovascular & Hematological Agents in Medicinal Chemistry Metaflammation: Tissue-Specific Alterations of the NLRP3 Inflammasome Platform in Metabolic Syndrome
Current Medicinal Chemistry Conditional Cardiac Overexpression of S100A6 Attenuates Myocyte Hypertrophy and Apoptosis Following Myocardial Infarction
Current Pharmaceutical Design Heart Failure Pharmacotherapy and Supports in the Elderly - A Short Review
Current Cardiology Reviews